Status:
UNKNOWN
Italian Observational Study of Patients With Acute Myeloid Leukemia Treated With Small Molecule Inhibiting BCL-2
Lead Sponsor:
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Collaborating Sponsors:
European Institute of Oncology
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
This is a multi-center retrospective observational study. Every patient with Acute Myeloid Leukemia (AML) treated with anti-B-cell lymphoma 2 (BCL2) treatment outside clinical trial from 1st January 2...
Detailed Description
In phase 1-2 studies, anti BCL-2 treatment has shown evidence of anti-leukemic activity as single agent and in combination and proved to be particularly effective in providing a deep response, with an...
Eligibility Criteria
Inclusion
- Patient with AML according to World Health Organization (WHO) 2016 classification
- Patient who have received any anti-BCL-2 treatment as single agent or in combination with other drugs from 1 Jan 2015 to 1 Apr 2019 outside clinical trials
Exclusion
- • Patient who have received any anti-BCL-2 treatment within a clinical trials
Key Trial Info
Start Date :
August 23 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04070807
Start Date
August 23 2019
End Date
December 1 2020
Last Update
April 21 2020
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
ASST Cremona
Cremona, CR, Italy, 26100
2
A.O. Pugliese Ciaccio
Catanzaro, CZ, Italy, 88100
3
Irst Irccs
Meldola, FC, Italy, 47014
4
AOU Careggi
Florence, FI, Italy